Omalizumab and treatment-resistant chronic spontaneous urticaria

Akyol A., ÖKTEM A., AKAY B. N., KUNDAKCI N., BOYVAT A.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.49, sa.3, ss.180-183, 2015 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4274/turkderm.22587
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.180-183
  • Anahtar Kelimeler: Chronic spontaneous urticaria, chronic urticaria, omalizumab, anti-IgE, treatment, DOSE OMALIZUMAB, CASE SERIES, EFFICACY, THERAPY, IGE
  • Ankara Üniversitesi Adresli: Evet

Özet

Background and Design: Humanized monoclonal antibody omalizumab was developed for the treatment of moderate-to-severe asthma. However, recently, reports on the successful use of omalizumab in the treatment of resistant chronic urticaria are increasing in the literature.